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Abstract
Purpose To quantify the retinal thickness and the refractive
error of the healthy human eye during hyperglycemia by
means of optical coherence tomography (OCT) and
Hartmann–Shack aberrometry.
Methods Hyperglycemia was induced in five healthy
subjects who were given a standard oral glucose tolerance
test (OGTT) after a subcutaneous injection of somatostatin.
Main outcome parameters were the central, pericentral and
peripheral thickness of the fovea, measured by means of
optical coherence tomography (OCT3). Ocular refractive
error was determined with Hartmann-Shack aberrometry.
Measurements at baseline and during maximal hyperglyce-
mia were analyzed, and a change was considered clinically
significant if the difference between the measurements
exceeded the threshold of 50 μm for retinal thickness and
0.2 D for refractive error.
Results During hyperglycemia (mean blood glucose level at
baseline: 4.0 mmol/l; mean maximal blood glucose level:
18.4 mmol/l) no significant changes could be found in the
central, pericentral, or peripheral foveal thickness in any of
the five subjects. One of the subjects had a hyperopic shift
of 0.4 D, but no significant change in refractive error was
found in any of the other subjects.
Conclusions The present study shows thatin healthy subjects
induced hyperglycemia does not affect retinal thickness, but it
can cause a small hyperopic shift of refraction.
Keywords Hyperglycemia.Diabetesmellitus.
Opticalcoherencetomography.Refractiveerrors
Patients with diabetes mellitus (DM) often experience
subjective symptoms of blurred vision associated to
hyperglycemia. The nature and origin of this phenomenon
are still unclear. Blurred vision during hyperglycemia could
be a result of transient refractive alterations due to changes
in the lens [5, 12, 15, 25, 27, 36, 37], but it could also be
caused by changes in the retina. Macular edema, or retinal
thickening due to abnormal fluid accumulation within the
macula, is a common cause of visual loss [1, 14, 22]. The
degree of retinal thickening has been found to be
significantly correlated with visual acuity [24]. Further-
more, a change in retinal thickness, resulting in a change in
axial eye length, could also induce a change in ocular
refractive error. For instance, it can be calculated that with a
50 μm increase in retinal thickness, the ocular refractive
error becomes 0.15 D more hyperopic [30].
Several studies have demonstrated that retinal thickness
is affected by DM [2, 7, 8, 18, 21, 23, 26, 32, 33, 35, 38].
In general, an increase in retinal thickness has been reported
in patients with long-term DM and advanced stages of
retinopathy [7, 8, 18, 32, 33, 35]. However, in diabetic
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decrease in retinal thickness has been observed [2, 23]. In
healthy subjects, it has been shown that the average retinal
thickness did not change during normo-insulinaemic
hyperglycemia [13].
It is unclear whether the thickness of the different retinal
areas, such as the foveal area, the pericentral foveal area,
and the peripheral foveal area, changes during acute
hyperglycemia and suppression of insulin. A change in
retinal thickness and/or ocular refractive error could explain
the subjective symptoms of blurred vision in patients with
DM and hyperglycemia. Therefore, in the present study the
effect of hyperglycemia on retinal thickness and ocular
refractive error was investigated in healthy subjects during
suppression of endogenous insulin. Retinal thickness was
measured by means of optical coherence tomography
(OCT), which is a non-invasive technique that provides
cross-sectional retinal images, and produces an objective
measurement of the retinal thickness, independent of the
refractive status of the eye [10, 11, 29]. Furthermore,
aberrometry was used to measure the ocular refractive error.
This technique makes it possible to detect small changes in
ocular refraction [19].
Subjects and methods
Five healthy subjects (two males and three females) partici-
patedinthestudy.Themeanageofthesubjectswas24.8years
(range 21.2–32.6), and their mean body mass index (BMI)
was 24.2 kg/m
2 (range 21.4–29.7). The subjects were
screened during a first visit, which included medical
history-taking, a physical examination (measurement of
visual acuity, weight, height and blood pressure) and
collecting a fasting blood sample. Exclusion criteria were a
history of DM (or a fasting plasma glucose >5.5 mmol/l), a
BMI of >30 kg/m
2, elevated blood pressure (>140 /
85 mmHg), a visual acuity of <0.5 (Snellen) or a history of
ocular pathology. The investigators of the ocular parameters
(NW and MD) were not informed about the blood glucose
levels. Furthermore, the investigators who induced hyper-
glycemia (EE and SS) were not informed about the results of
the ocular measurements. The study protocol was approved
by the Medical Ethics Committee of the VU University
Medical Center in Amsterdam, and written informed consent
was obtained from all subjects after the purpose and nature
of the study had been explained to them.
Procedure to induce hyperglycemia
After a 10-hour overnight fast, the subjects were given a
subcutaneous injection of a low dose (100 μg) of synthetic
somatostatin (Sandostatin, Novartis, Basel, Switzerland) in
order to suppress endogenous insulin secretion. Each
subject underwent an oral glucose tolerance test (OGTT)
(75 g glucose) 30 minutes after the somatostatin injection,
and blood glucose levels were measured with a blood
glucose analyzer (HemoCue Diagnostics BV, Oisterwijk,
the Netherlands). Endogenous insulin levels were measured
by means of immunometric assays (Luminescence, Bayer
Diagnostics, Mijdrecht, the Netherlands) in the Endocrinol-
ogy Laboratory at the Department of Clinical Chemistry of
the VU University Medical Center. The subjects remained
in fasting state during the entire procedure.
Ocular measurements
Retinal thickness was measured with the Stratus OCT
(Model 3000, Carl Zeiss Meditec, Dublin, CA, USA),
which combines a low-coherence scanning interferometer
(wavelength 820 nm) with a video camera to visualize the
fundus of the eye. The fast macular thickness OCT scan
protocol was used to obtain six cross-sectional macular
scans, 6 mm in length, which were positioned at equally
spaced angular orientations (30°) centred on the fovea. The
cross-sectional images were analyzed with OCT3 mapping
software that uses an edge-detection technique to locate the
vitreoretinal interface and the anterior surface of the retinal
pigment epithelium. Retinal thickness was defined as the
distance between these two surfaces. Two OCT scans were
made of each subject before, and every 30 minutes during
the period of hyperglycemia. In order to quantify the retinal
thickness, the foveal map constructed by the software was
divided into nine Early Treatment Diabetic Retinopathy
Study (ETDRS) areas [6]: the central fovea (central circle
with a diameter of 1 mm), and the pericentral area (donut-
shaped ring with an inner diameter of 1 mm and an outer
diameter of 3 mm) and peripheral area (donut-shaped ring
with an inner diameter of 3 mm and an outer diameter of
6 mm), both of which were divided into four quadrants.
Retinal thickness was calculated for all separate areas, and
for the average pericentral and peripheral regions.
Ocular refractive error was determined with an IRX3
aberrometer (Imagine Eye Optics, Paris, France), which per-
forms wavefront analysis of the eye according to the
Hartmann-Shack principle [19]. After pupil dilation and
paralysis of accommodation with 1.0% cyclopentolate and
5.0% phenylephrine eye-drops, a series of three aberrometry
measurements was made before, and every 30 minutes
during the hyperglycemic condition. From these measure-
ments, the equivalent refractive error was calculated as:
equivalent refractive error (ERE) = sphere + (cylinder / 2).
The measurements at baseline and during maximal
hyperglycemia were analyzed, and any change was consid-
704 Graefes Arch Clin Exp Ophthalmol (2008) 246:703–708ered to be meaningful if the difference between the
measurements was greater than the threshold of 50 μm for
retinal thickness and 0.2 diopters (D) for ERE. The
threshold of 50 μm exceeded the 95% confidence interval
for the detection of a change in retinal thickness, which has
been reported to be approximately 40 μm[ 4, 20, 28]. A
refractive change of more than 0.2 D also surpasses the
precision (defined as 95% confidence interval) of the
aberrometer for measuring sphere, cylinder, and conse-
quently ERE [3, 31]. In each subject, the significance of a
change was obtained from the precision of the measurement
instruments and the difference in the ocular parameters at
baseline and during hyperglycemia. In the whole group, the
significance of a change could be determined by means of
Wilcoxon matched pairs signed rank sum tests. P-values
≤0.05 were considered to be statistically significant.
Results
The changes in blood glucose after the administration of
somatostatin and glucose are shown in Fig. 1. Mean blood
glucose levels rose from 4.0 mmol/l (range 3.4–4.5 mmol/l)
to 18.4 mmol/l (range 16.1–22.0 mmol/l) after the OGTT.
Endogenous insulin was suppressed by the subcutaneous
injection of somatostatin during the glucose load to a mean
value of 2.1 pmol/l (range 0.4–4.5 pmol/l), and remained
below basal secretion level (<110.0 pmol/l) for 147 minutes
(range 75–270 minutes). Subject 01 had a delayed elevation
of blood glucose level, compared to the other subjects. This
person received a second 75 g oral glucose load after
30 minutes in order to induce a rise in the blood glucose
level. In all subjects, the blood glucose and endogenous
insulin levels normalized within 6 hours after the OGTT.
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Fig. 1 Graph of normalized blood glucose levels in the five subjects
after the administration of somatostatin and glucose. Data are
normalized by subtracting the value at baseline from the measured
value in each subject. The oral glucose load (75 g) was administered at
T 0. Subject 01 received an extra 75 g oral glucose load at T 30
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Fig. 2 Graph of the normalized equivalent refractive error (ERE) in
diopters (D) of the five subjects. Data are presented as mean±SD;
three measurements were made of each subject every 30 minutes
during the procedure. Data are normalized by subtracting the value at
baseline from the measured value in each subject. The oral glucose
load was administered at T 0. * Significant difference between ERE at
T 0 and T 210 (maximal hyperglycemia), p<0.001
Graefes Arch Clin Exp Ophthalmol (2008) 246:703–708 705Figure 2 shows the normalized ERE of the five subjects
during hyperglycemia. Mean ERE at baseline was 0.6 D
(SD 0.6) and 0.7 D (SD 0.6) during maximal hyperglyce-
mia; no significant change was found in the group as a
whole. A small, but significant hyperopic shift of 0.4 D (SD
0.2) in ERE was measured in subject 01 during maximal
hyperglycemia, compared to the start of the procedure (p<
0.001). No significant change in ERE was found in any of
the other subjects. Normalized retinal thickness parameters
are shown in Fig. 3a (central foveal area), Fig. 3b (average
pericentral foveal area) and Fig. 3c (average peripheral
foveal area). Average central foveal thickness, average
pericentral foveal thickness, and average peripheral foveal
thickness at baseline were 202 μm (SD 8), 277 μm (SD 5),
and 243 μm (SD 8). During maximal hyperglycemia,
average central foveal thickness, average pericentral foveal
thickness, and average peripheral foveal thickness were
203 μm (SD 7), 275 μm (SD 3), and 242 μm (SD 9). No
significant differences were found in the group as a whole.
Furthermore, none of the subjects had any significant
changes in the thickness of the central fovea, the peri-
central fovea, or the peripheral fovea during maximal
hyperglycemia, compared to baseline. The nine separate
ETDRS areas were not affected by hyperglycemia. At
baseline and during hyperglycemia, any change in retinal
thickness that occurred in the various areas was less than
15 μm, which was within the previously defined threshold
of 50 μm.
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Fig. 3 Graphs and maps of
normalized retinal thickness
parameters in the five subjects
during hyperglycemia: (a) cen-
tral fovea, (b) pericentral fovea,
(c) peripheral fovea. Data are
normalized by subtracting the
value at baseline from the mea-
sured value in each subject.
Each measured area has been
indicated by a dark grey area on
the retinal maps. No significant
changes in retinal parameters
were found in any of the sub-
jects. The oral glucose load was
administered at T 0
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Blurred vision is a symptom that occurs frequently in
patients with DM and hyperglycemia. The underlying
mechanism is still unclear, and therefore the present study
was carried out in an attempt to identify a possible cause of
this symptom. The effect of reproducible hyperglycemia on
retinal thickness and refractive error was studied in healthy
young subjects who did not suffer from the systemic effects
of DM.
No changes in the thickness of the central, pericentral or
peripheral foveal areas were found in any of the subjects
during hyperglycemia. In addition, no significant change
was measured in any of the nine different ETDRS areas of
the macula. In their study, Jeppesen et al. [13] also found no
significant difference in retinal thickness in healthy subjects
during normo-insulinaemic hyperglycemia. Before and
180 minutes after the start of a hyperglycemic clamp they
measured the average thickness of the retina, and found that
retinal thickness was not affected by hyperglycemia.
Although in the present study retinal thickness was
measured under different circumstances than in the study
of Jeppesen et al. (hypo-insulinaemic hyperglycemia
instead of normo-insulinaemic hyperglycemia), the results
confirm those of Jeppesen et al.
Retinal thickness has been reported to change in patients
with long-term DM and retinopathy. A morphological change
in the retina may even occur in the early stages of diabetic
retinopathy [2, 7, 8, 18, 21, 23, 26, 32, 33, 35, 38]. These
changes in retinal thickness are usually due to abnormal fluid
accumulation resulting from a breakdown of the blood-
retinal barrier [34]. Goebel et al. [8] measured retinal
thickness by means of OCT in 136 patients with different
stages of diabetic retinopathy and with a mean DM duration
of 16 years. Mean foveal thickness was 307±136 μmi nt h e
diabetic subjects, compared to 153±15 μm in healthy
subjects. It seems that only long-term hyperglycemia and/or
long-term fluctuations in blood glucose levels have any
significant influence on the blood–retina barrier and retinal
thickness. From the findings of the present study, it appears
that the blood–retina barrier does not seem to be affected by
a single episode of acute hyperglycemia. Nevertheless, the
fact that no change in retinal thickness could be determined
does not exclude the possibility that there could be early
dysfunction of the blood retina barrier. Other means of
examination could evidence such a dysfunction of the blood
retina barrier following acute hyperglycemia.
A factor that could have biased the results of this study is
the administration of a synthetic somatostatin analogue to
the subjects. Somatostatin is a peptide hormone that inhibits
several hormones, including IGF-1 and insulin. IGF-1 is
a growth factor that is produced by the hypoxic retina to
mediate angiogenesis, resulting in neovascularisation.
Somatostatin analogues not only inhibit neovascularisation
in patients with advanced diabetic retinopathy, but also
stabilize the blood–retinal barrier in patients with diabetic
macular edema [16, 17]. It could have been possible that in
the present study an increase in retinal thickness during
hyperglycemia was prevented by somatostatin. Neverthe-
less, the efficacy of synthetic somatostatin in the treatment
of advanced diabetic retinopathy was investigated by Grant
et al. [9]. With maximally tolerated doses of somatostatin
(ranging from 200 to 5000 μg/day), after a period of
15 months one out of 22 eyes required panretinal
photocoagulation, compared to nine of 24 eyes that were
not treated with somatostatin. From the results of the Grant
et al. study, it seems that only frequent, large doses of
somatostatin over a long period of time have any significant
effect on the progression of diabetic retinopathy. Although
the effect of somatostatin on the healthy retina has not been
investigated yet, it seems to be unlikely that the results of
the present study were biased by the administration of one
single, low dose (100 μg) of somatostatin.
In conclusion, the results of this study indicate that in
healthy subjects, hyperglycemia does not cause any change
in retinal thickness. Furthermore, ocular refraction in
general was not affected by hyperglycemia. However, there
were interindividual variations, as illustrated by subject 01,
who had a hyperopic shift of refraction during hyperglyce-
mia. Therefore, it seems that a refractive change during
hyperglycemia cannot be explained by a change in retinal
thickness. It could well be that other refractive components,
such as the lens, are involved in causing blurred vision and
refractive alterations during hyperglycemia.
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